|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Complex (apoptosis/peptide)
|
|
|
Title:
|
|
Structure of bcl-xl/bak peptide complex, nmr, minimized average structure
|
|
Structure:
|
|
Bcl-xl. Chain: a. Engineered: yes. Bak peptide. Chain: b. Fragment: residues 572 - 587 of bak protein. Engineered: yes
|
|
Source:
|
|
Escherichia coli. Organism_taxid: 562. Strain: hms174 (de3). Expressed in: escherichia coli. Expression_system_taxid: 562. 205, deletion mutant lacking a flexible loop (residues 45- 84) and thE C-terminal hydrophobic region, with a c- terminal his-tag.
|
|
NMR struc:
|
|
1 models
|
|
|
Authors:
|
|
M.Sattler,H.Liang,D.Nettesheim,R.P.Meadows,J.E.Harlan, M.Eberstadt,H.Yoon,S.B.Shuker,B.S.Chang,A.J.Minn, C.B.Thompson,S.W.Fesik
|
Key ref:
|
|
M.Sattler
et al.
(1997).
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Science,
275,
983-986.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
16-Oct-96
|
Release date:
|
29-Oct-97
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cellular component
|
Bcl-2 family protein complex
|
15 terms
|
|
|
Biological process
|
growth
|
36 terms
|
|
|
Biochemical function
|
protein binding
|
3 terms
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Science
275:983-986
(1997)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
|
|
M.Sattler,
H.Liang,
D.Nettesheim,
R.P.Meadows,
J.E.Harlan,
M.Eberstadt,
H.S.Yoon,
S.B.Shuker,
B.S.Chang,
A.J.Minn,
C.B.Thompson,
S.W.Fesik.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
Heterodimerization between members of the Bcl-2 family of proteins is a key
event in the regulation of programmed cell death. The molecular basis for
heterodimer formation was investigated by determination of the solution
structure of a complex between the survival protein Bcl-xL and the
death-promoting region of the Bcl-2-related protein Bak. The structure and
binding affinities of mutant Bak peptides indicate that the Bak peptide adopts
an amphipathic alpha helix that interacts with Bcl-xL through hydrophobic and
electrostatic interactions. Mutations in full-length Bak that disrupt either
type of interaction inhibit the ability of Bak to heterodimerize with Bcl-xL.
|
|
|
|
|
|
| |
Selected figure(s)
|
|
|
|
| |
|
|
|
|
|
|
Figure 1.
Fig. 1. (A) Stereoview of the backbone (N, C^  , C
 ) of 15
superimposed NMR-derived structures of Bcl-x[L] (shown in black)
complexed^ with the 16-amino acid Bak peptide (shown in red).
(B) Ribbons (21) depiction of the averaged minimized NMR
structure^ for the complex. The BH1, BH2, and BH3 regions of
Bcl-x[L] are shown in yellow, red, and green, respectively. The
Bak peptide is shown in magenta.
|
|
Figure 2.
Fig. 2. (A) Surface representation of the binding pocket of
Bcl-x[L] bound to the Bak peptide. Hydrophobic residues showing
NOEs to the peptide are colored in yellow, whereas Arg139/Arg100
and Glu129 are colored in blue and red, respectively. Residues
of Bcl-x[L] are labeled in white and the Bak peptide in black.
(B) Depiction of the side chains in the binding site of
Bcl-x[L]. Hydrophobic^ side chains of the protein showing NOEs
to the peptide are colored^ in yellow. Side chains of positively
and negatively charged side^ chains interacting with the peptide
are colored in blue and red, respectively. The peptide side
chains are colored by atom type. Residues of Bcl-x[L] and the
Bak peptide are labeled in black and^ green, respectively.
|
|
|
|
|
|
| |
The above figures are
reprinted
by permission from the AAAs:
Science
(1997,
275,
983-986)
copyright 1997.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
A.S.Azmi,
Z.Wang,
P.A.Philip,
R.M.Mohammad,
and
F.H.Sarkar
(2011).
Emerging Bcl-2 inhibitors for the treatment of cancer.
|
| |
Expert Opin Emerg Drugs, 16,
59-70.
|
|
|
|
|
|
|
A.Shamas-Din,
H.Brahmbhatt,
B.Leber,
and
D.W.Andrews
(2011).
BH3-only proteins: Orchestrators of apoptosis.
|
| |
Biochim Biophys Acta, 1813,
508-520.
|
|
|
|
|
|
|
B.Juhásová,
I.Bhatia-Kiššová,
K.Polčicová,
M.Mentel,
M.Forte,
and
P.Polčic
(2011).
Reconstitution of interactions of Murine gammaherpesvirus 68 M11 with Bcl-2 family proteins in yeast.
|
| |
Biochem Biophys Res Commun, 407,
783-787.
|
|
|
|
|
|
|
B.Ku,
C.Liang,
J.U.Jung,
and
B.H.Oh
(2011).
Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX.
|
| |
Cell Res, 21,
627-641.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
B.Zhou,
X.Li,
Y.Li,
Y.Xu,
Z.Zhang,
M.Zhou,
X.Zhang,
Z.Liu,
J.Zhou,
C.Cao,
B.Yu,
and
R.Wang
(2011).
Discovery and development of thiazolo[3,2-a]pyrimidinone derivatives as general inhibitors of Bcl-2 family proteins.
|
| |
ChemMedChem, 6,
904-921.
|
|
|
|
|
|
|
C.Katz,
L.Levy-Beladev,
S.Rotem-Bamberger,
T.Rito,
S.G.Rüdiger,
and
A.Friedler
(2011).
Studying protein-protein interactions using peptide arrays.
|
| |
Chem Soc Rev, 40,
2131-2145.
|
|
|
|
|
|
|
D.Westphal,
G.Dewson,
P.E.Czabotar,
and
R.M.Kluck
(2011).
Molecular biology of Bax and Bak activation and action.
|
| |
Biochim Biophys Acta, 1813,
521-531.
|
|
|
|
|
|
|
E.F.Lee,
O.B.Clarke,
M.Evangelista,
Z.Feng,
T.P.Speed,
E.B.Tchoubrieva,
A.Strasser,
B.H.Kalinna,
P.M.Colman,
and
W.D.Fairlie
(2011).
Discovery and molecular characterization of a Bcl-2-regulated cell death pathway in schistosomes.
|
| |
Proc Natl Acad Sci U S A, 108,
6999-7003.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
J.Lindsay,
M.D.Esposti,
and
A.P.Gilmore
(2011).
Bcl-2 proteins and mitochondria--specificity in membrane targeting for death.
|
| |
Biochim Biophys Acta, 1813,
532-539.
|
|
|
|
|
|
|
M.Guharoy,
A.Pal,
M.Dasgupta,
and
P.Chakrabarti
(2011).
PRICE (PRotein Interface Conservation and Energetics): a server for the analysis of protein-protein interfaces.
|
| |
J Struct Funct Genomics, 12,
33-41.
|
|
|
|
|
|
|
T.A.Fuchsluger,
U.Jurkunas,
A.Kazlauskas,
and
R.Dana
(2011).
Corneal endothelial cells are protected from apoptosis by gene therapy.
|
| |
Hum Gene Ther, 22,
549-558.
|
|
|
|
|
|
|
A.Tripathi,
and
G.E.Kellogg
(2010).
A novel and efficient tool for locating and characterizing protein cavities and binding sites.
|
| |
Proteins, 78,
825-842.
|
|
|
|
|
|
|
B.Leibowitz,
and
J.Yu
(2010).
Mitochondrial signaling in cell death via the Bcl-2 family.
|
| |
Cancer Biol Ther, 9,
417-422.
|
|
|
|
|
|
|
C.R.Braun,
J.Mintseris,
E.Gavathiotis,
G.H.Bird,
S.P.Gygi,
and
L.D.Walensky
(2010).
Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome.
|
| |
Chem Biol, 17,
1325-1333.
|
|
|
|
|
|
|
D.M.Hockenbery
(2010).
Targeting mitochondria for cancer therapy.
|
| |
Environ Mol Mutagen, 51,
476-489.
|
|
|
|
|
|
|
E.Fire,
S.V.Gullá,
R.A.Grant,
and
A.E.Keating
(2010).
Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes.
|
| |
Protein Sci, 19,
507-519.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
E.Gavathiotis,
D.E.Reyna,
M.L.Davis,
G.H.Bird,
and
L.D.Walensky
(2010).
BH3-triggered structural reorganization drives the activation of proapoptotic BAX.
|
| |
Mol Cell, 40,
481-492.
|
|
|
|
|
|
|
F.Campbell,
J.P.Plante,
T.A.Edwards,
S.L.Warriner,
and
A.J.Wilson
(2010).
N-alkylated oligoamide alpha-helical proteomimetics.
|
| |
Org Biomol Chem, 8,
2344-2351.
|
|
|
|
|
|
|
F.Hagn,
C.Klein,
O.Demmer,
N.Marchenko,
A.Vaseva,
U.M.Moll,
and
H.Kessler
(2010).
BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain.
|
| |
J Biol Chem, 285,
3439-3450.
|
|
|
|
|
|
|
G.J.Rautureau,
C.L.Day,
and
M.G.Hinds
(2010).
Intrinsically disordered proteins in bcl-2 regulated apoptosis.
|
| |
Int J Mol Sci, 11,
1808-1824.
|
|
|
|
|
|
|
H.Zhao,
W.Guo,
C.Peng,
T.Ji,
and
X.Lu
(2010).
Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis.
|
| |
Mol Biol Rep, 37,
2509-2515.
|
|
|
|
|
|
|
J.Y.Zheng,
and
N.N.Boustany
(2010).
Alterations in the characteristic size distributions of subcellular scatterers at the onset of apoptosis: effect of Bcl-xL and Bax/Bak.
|
| |
J Biomed Opt, 15,
045002.
|
|
|
|
|
|
|
L.Fischer,
and
G.Guichard
(2010).
Folding and self-assembly of aromatic and aliphatic urea oligomers: towards connecting structure and function.
|
| |
Org Biomol Chem, 8,
3101-3117.
|
|
|
|
|
|
|
L.Prochazka,
L.F.Dong,
K.Valis,
R.Freeman,
S.J.Ralph,
J.Turanek,
and
J.Neuzil
(2010).
alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels.
|
| |
Apoptosis, 15,
782-794.
|
|
|
|
|
|
|
L.Sborgi,
S.Barrera-Vilarmau,
P.Obregón,
and
E.de Alba
(2010).
Characterization of a novel interaction between Bcl-2 members Diva and Harakiri.
|
| |
PLoS One, 5,
e15575.
|
|
|
|
|
|
|
M.L.Stewart,
E.Fire,
A.E.Keating,
and
L.D.Walensky
(2010).
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer.
|
| |
Nat Chem Biol, 6,
595-601.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
M.Vogler,
S.D.Furdas,
M.Jung,
T.Kuwana,
M.J.Dyer,
and
G.M.Cohen
(2010).
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
|
| |
Clin Cancer Res, 16,
4217-4225.
|
|
|
|
|
|
|
N.London,
B.Raveh,
D.Movshovitz-Attias,
and
O.Schueler-Furman
(2010).
Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions?
|
| |
Proteins, 78,
3140-3149.
|
|
|
|
|
|
|
S.Bleicken,
M.Classen,
P.V.Padmavathi,
T.Ishikawa,
K.Zeth,
H.J.Steinhoff,
and
E.Bordignon
(2010).
Molecular details of Bax activation, oligomerization, and membrane insertion.
|
| |
J Biol Chem, 285,
6636-6647.
|
|
|
|
|
|
|
S.Campbell,
B.Hazes,
M.Kvansakul,
P.Colman,
and
M.Barry
(2010).
Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1.
|
| |
J Biol Chem, 285,
4695-4708.
|
|
|
|
|
|
|
S.Kurtulus,
P.Tripathi,
J.T.Opferman,
and
D.A.Hildeman
(2010).
Contracting the 'mus cells'--does down-sizing suit us for diving into the memory pool?
|
| |
Immunol Rev, 236,
54-67.
|
|
|
|
|
|
|
A.J.García-Sáez,
J.Ries,
M.Orzáez,
E.Pérez-Payà,
and
P.Schwille
(2009).
Membrane promotes tBID interaction with BCL(XL).
|
| |
Nat Struct Mol Biol, 16,
1178-1185.
|
|
|
|
|
|
|
A.M.Almerico,
M.Tutone,
and
A.Lauria
(2009).
In-silico screening of new potential Bcl-2/Bcl-xl inhibitors as apoptosis modulators.
|
| |
J Mol Model, 15,
349-355.
|
|
|
|
|
|
|
E.F.Lee,
A.Fedorova,
K.Zobel,
M.J.Boyle,
H.Yang,
M.A.Perugini,
P.M.Colman,
D.C.Huang,
K.Deshayes,
and
W.D.Fairlie
(2009).
Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins.
|
| |
J Biol Chem, 284,
31315-31326.
|
|
|
|
|
|
|
E.F.Lee,
J.D.Sadowsky,
B.J.Smith,
P.E.Czabotar,
K.J.Peterson-Kaufman,
P.M.Colman,
S.H.Gellman,
and
W.D.Fairlie
(2009).
High-resolution structural characterization of a helical alpha/beta-peptide foldamer bound to the anti-apoptotic protein Bcl-xL.
|
| |
Angew Chem Int Ed Engl, 48,
4318-4322.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
E.F.Lee,
P.E.Czabotar,
H.Yang,
B.E.Sleebs,
G.Lessene,
P.M.Colman,
B.J.Smith,
and
W.D.Fairlie
(2009).
Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
|
| |
J Biol Chem, 284,
30508-30517.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
G.Brien,
A.L.Debaud,
X.Robert,
L.Oliver,
M.C.Trescol-Biemont,
N.Cauquil,
O.Geneste,
N.Aghajari,
F.M.Vallette,
R.Haser,
and
N.Bonnefoy-Berard
(2009).
C-terminal residues regulate localization and function of the antiapoptotic protein Bfl-1.
|
| |
J Biol Chem, 284,
30257-30263.
|
|
|
|
|
|
|
G.Dewson,
and
R.M.Kluck
(2009).
Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis.
|
| |
J Cell Sci, 122,
2801-2808.
|
|
|
|
|
|
|
G.Moroy,
E.Martin,
A.Dejaegere,
and
R.H.Stote
(2009).
Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions.
|
| |
J Biol Chem, 284,
17499-17511.
|
|
|
|
|
|
|
H.Dai,
X.W.Meng,
S.H.Lee,
P.A.Schneider,
and
S.H.Kaufmann
(2009).
Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis.
|
| |
J Biol Chem, 284,
18311-18322.
|
|
|
|
|
|
|
H.Kim,
H.C.Tu,
D.Ren,
O.Takeuchi,
J.R.Jeffers,
G.P.Zambetti,
J.J.Hsieh,
and
E.H.Cheng
(2009).
Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.
|
| |
Mol Cell, 36,
487-499.
|
|
|
|
|
|
|
J.M.Rodriguez,
L.Nevola,
N.T.Ross,
G.I.Lee,
and
A.D.Hamilton
(2009).
Synthetic inhibitors of extended helix-protein interactions based on a biphenyl 4,4'-dicarboxamide scaffold.
|
| |
Chembiochem, 10,
829-833.
|
|
|
|
|
|
|
J.M.Rodriguez,
N.T.Ross,
W.P.Katt,
D.Dhar,
G.I.Lee,
and
A.D.Hamilton
(2009).
Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface.
|
| |
ChemMedChem, 4,
649-656.
|
|
|
|
|
|
|
J.Sun,
D.M.Abdeljabbar,
N.Clarke,
M.L.Bellows,
C.A.Floudas,
and
A.J.Link
(2009).
Reconstitution and engineering of apoptotic protein interactions on the bacterial cell surface.
|
| |
J Mol Biol, 394,
297-305.
|
|
|
|
|
|
|
J.Wei,
M.F.Rega,
S.Kitada,
H.Yuan,
D.Zhai,
P.Risbood,
H.H.Seltzman,
C.E.Twine,
J.C.Reed,
and
M.Pellecchia
(2009).
Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists.
|
| |
Cancer Lett, 273,
107-113.
|
|
|
|
|
|
|
K.R.Rockwell,
and
B.T.Huber
(2009).
Biologically distinct conformations of Bcl-x can be resolved using 2D isoelectric focusing.
|
| |
Mol Immunol, 46,
1605-1612.
|
|
|
|
|
|
|
M.Orzáez,
A.Gortat,
L.Mondragón,
and
E.Pérez-Payá
(2009).
Peptides and peptide mimics as modulators of apoptotic pathways.
|
| |
ChemMedChem, 4,
146-160.
|
|
|
|
|
|
|
N.S.Chari,
N.L.Pinaire,
L.Thorpe,
L.J.Medeiros,
M.J.Routbort,
and
T.J.McDonnell
(2009).
The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.
|
| |
Apoptosis, 14,
336-347.
|
|
|
|
|
|
|
R.Besch,
H.Poeck,
T.Hohenauer,
D.Senft,
G.Häcker,
C.Berking,
V.Hornung,
S.Endres,
T.Ruzicka,
S.Rothenfusser,
and
G.Hartmann
(2009).
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.
|
| |
J Clin Invest, 119,
2399-2411.
|
|
|
|
|
|
|
R.L.van Montfort,
and
P.Workman
(2009).
Structure-based design of molecular cancer therapeutics.
|
| |
Trends Biotechnol, 27,
315-328.
|
|
|
|
|
|
|
S.Oda,
M.Schröder,
and
A.R.Khan
(2009).
Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7.
|
| |
Structure, 17,
1528-1537.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
W.Novak,
H.Wang,
and
G.Krilov
(2009).
Role of protein flexibility in the design of Bcl-X(L) targeting agents: insight from molecular dynamics.
|
| |
J Comput Aided Mol Des, 23,
49-61.
|
|
|
|
|
|
|
W.Wolfson
(2009).
Aileron staples peptides.
|
| |
Chem Biol, 16,
910-912.
|
|
|
|
|
|
|
Y.Yao,
A.A.Bobkov,
L.A.Plesniak,
and
F.M.Marassi
(2009).
Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL.
|
| |
Biochemistry, 48,
8704-8711.
|
|
|
|
|
|
|
Y.Yao,
and
F.M.Marassi
(2009).
BAX and BAK caught in the act.
|
| |
Mol Cell, 36,
353-354.
|
|
|
|
|
|
|
Y.Zhan,
G.Jia,
D.Wu,
Y.Xu,
and
L.Xu
(2009).
Design and synthesis of a gossypol derivative with improved antitumor activities.
|
| |
Arch Pharm (Weinheim), 342,
223-229.
|
|
|
|
|
|
|
A.G.Letai
(2008).
Diagnosing and exploiting cancer's addiction to blocks in apoptosis.
|
| |
Nat Rev Cancer, 8,
121-132.
|
|
|
|
|
|
|
A.M.Strohecker,
F.Yehiely,
F.Chen,
and
V.L.Cryns
(2008).
Caspase cleavage of HER-2 releases a Bad-like cell death effector.
|
| |
J Biol Chem, 283,
18269-18282.
|
|
|
|
|
|
|
B.Ku,
J.S.Woo,
C.Liang,
K.H.Lee,
H.S.Hong,
X.E,
K.S.Kim,
J.U.Jung,
and
B.H.Oh
(2008).
Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine gamma-herpesvirus 68.
|
| |
PLoS Pathog, 4,
e25.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
C.Grills,
N.Crawford,
A.Chacko,
P.G.Johnston,
F.O'Rourke,
and
D.A.Fennell
(2008).
Dynamical systems analysis of mitochondrial BAK activation kinetics predicts resistance to BH3 domains.
|
| |
PLoS ONE, 3,
e3038.
|
|
|
|
|
|
|
C.Katz,
H.Benyamini,
S.Rotem,
M.Lebendiker,
T.Danieli,
A.Iosub,
H.Refaely,
M.Dines,
V.Bronner,
T.Bravman,
D.E.Shalev,
S.Rüdiger,
and
A.Friedler
(2008).
Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2.
|
| |
Proc Natl Acad Sci U S A, 105,
12277-12282.
|
|
|
|
|
|
|
C.Smits,
P.E.Czabotar,
M.G.Hinds,
and
C.L.Day
(2008).
Structural plasticity underpins promiscuous binding of the prosurvival protein A1.
|
| |
Structure, 16,
818-829.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
D.L.Dai,
Y.Wang,
M.Liu,
M.Martinka,
and
G.Li
(2008).
Bim expression is reduced in human cutaneous melanomas.
|
| |
J Invest Dermatol, 128,
403-407.
|
|
|
|
|
|
|
D.Lama,
and
R.Sankararamakrishnan
(2008).
Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations.
|
| |
Proteins, 73,
492-514.
|
|
|
|
|
|
|
D.Tian,
S.G.Das,
J.M.Doshi,
J.Peng,
J.Lin,
and
C.Xing
(2008).
sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.
|
| |
Cancer Lett, 259,
198-208.
|
|
|
|
|
|
|
D.Zhai,
C.Jin,
Z.Huang,
A.C.Satterthwait,
and
J.C.Reed
(2008).
Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1.
|
| |
J Biol Chem, 283,
9580-9586.
|
|
|
|
|
|
|
E.F.Lee,
L.Chen,
H.Yang,
P.M.Colman,
D.C.Huang,
and
W.D.Fairlie
(2008).
EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency.
|
| |
Cell Death Differ, 15,
1609-1618.
|
|
|
|
|
|
|
E.F.Lee,
P.E.Czabotar,
M.F.van Delft,
E.M.Michalak,
M.J.Boyle,
S.N.Willis,
H.Puthalakath,
P.Bouillet,
P.M.Colman,
D.C.Huang,
and
W.D.Fairlie
(2008).
A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.
|
| |
J Cell Biol, 180,
341-355.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
E.Gavathiotis,
M.Suzuki,
M.L.Davis,
K.Pitter,
G.H.Bird,
S.G.Katz,
H.C.Tu,
H.Kim,
E.H.Cheng,
N.Tjandra,
and
L.D.Walensky
(2008).
BAX activation is initiated at a novel interaction site.
|
| |
Nature, 455,
1076-1081.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
E.Lomonosova,
and
G.Chinnadurai
(2008).
BH3-only proteins in apoptosis and beyond: an overview.
|
| |
Oncogene, 27,
S2-19.
|
|
|
|
|
|
|
F.A.Sinicrope,
R.L.Rego,
K.Okumura,
N.R.Foster,
M.J.O'Connell,
D.J.Sargent,
and
H.E.Windschitl
(2008).
Prognostic impact of bim, puma, and noxa expression in human colon carcinomas.
|
| |
Clin Cancer Res, 14,
5810-5818.
|
|
|
|
|
|
|
G.Chinnadurai,
S.Vijayalingam,
and
S.B.Gibson
(2008).
BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions.
|
| |
Oncogene, 27,
S114-S127.
|
|
|
|
|
|
|
G.Dewson,
T.Kratina,
H.W.Sim,
H.Puthalakath,
J.M.Adams,
P.M.Colman,
and
R.M.Kluck
(2008).
To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions.
|
| |
Mol Cell, 30,
369-380.
|
|
|
|
|
|
|
G.Lessene,
P.E.Czabotar,
and
P.M.Colman
(2008).
BCL-2 family antagonists for cancer therapy.
|
| |
Nat Rev Drug Discov, 7,
989.
|
|
|
|
|
|
|
I.Galindo,
B.Hernaez,
G.Díaz-Gil,
J.M.Escribano,
and
C.Alonso
(2008).
A179L, a viral Bcl-2 homologue, targets the core Bcl-2 apoptotic machinery and its upstream BH3 activators with selective binding restrictions for Bid and Noxa.
|
| |
Virology, 375,
561-572.
|
|
|
|
|
|
|
J.C.Reed
(2008).
Bcl-2-family proteins and hematologic malignancies: history and future prospects.
|
| |
Blood, 111,
3322-3330.
|
|
|
|
|
|
|
J.I.Fletcher,
S.Meusburger,
C.J.Hawkins,
D.T.Riglar,
E.F.Lee,
W.D.Fairlie,
D.C.Huang,
and
J.M.Adams
(2008).
Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax.
|
| |
Proc Natl Acad Sci U S A, 105,
18081-18087.
|
|
|
|
|
|
|
J.K.Yang
(2008).
FLIP as an anti-cancer therapeutic target.
|
| |
Yonsei Med J, 49,
19-27.
|
|
|
|
|
|
|
J.Y.Zheng,
Y.C.Tsai,
P.Kadimcherla,
R.Zhang,
J.Shi,
G.A.Oyler,
and
N.N.Boustany
(2008).
The C-terminal transmembrane domain of Bcl-xL mediates changes in mitochondrial morphology.
|
| |
Biophys J, 94,
286-297.
|
|
|
|
|
|
|
K.Katayama,
S.Tsukiji,
T.Furuta,
and
T.Nagamune
(2008).
A bromocoumarin-based linker for synthesis of photocleavable peptidoconjugates with high photosensitivity.
|
| |
Chem Commun (Camb), 0,
5399-5401.
|
|
|
|
|
|
|
K.W.Yip,
and
J.C.Reed
(2008).
Bcl-2 family proteins and cancer.
|
| |
Oncogene, 27,
6398-6406.
|
|
|
|
|
|
|
L.P.Billen,
A.Shamas-Din,
and
D.W.Andrews
(2008).
Bid: a Bax-like BH3 protein.
|
| |
Oncogene, 27,
S93-104.
|
|
|
|
|
|
|
L.P.Billen,
C.L.Kokoski,
J.F.Lovell,
B.Leber,
and
D.W.Andrews
(2008).
Bcl-XL inhibits membrane permeabilization by competing with Bax.
|
| |
PLoS Biol, 6,
e147.
|
|
|
|
|
|
|
L.Wang,
F.Kong,
C.L.Kokoski,
D.W.Andrews,
and
C.Xing
(2008).
Development of dimeric modulators for anti-apoptotic Bcl-2 proteins.
|
| |
Bioorg Med Chem Lett, 18,
236-240.
|
|
|
|
|
|
|
M.D.Boersma,
J.D.Sadowsky,
Y.A.Tomita,
and
S.H.Gellman
(2008).
Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: application to the Bim BH3 domain.
|
| |
Protein Sci, 17,
1232-1240.
|
|
|
|
|
|
|
M.Giam,
D.C.Huang,
and
P.Bouillet
(2008).
BH3-only proteins and their roles in programmed cell death.
|
| |
Oncogene, 27,
S128-S136.
|
|
|
|
|
|
|
M.Kvansakul,
H.Yang,
W.D.Fairlie,
P.E.Czabotar,
S.F.Fischer,
M.A.Perugini,
D.C.Huang,
and
P.M.Colman
(2008).
Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
|
| |
Cell Death Differ, 15,
1564-1571.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
M.R.Warr,
and
G.C.Shore
(2008).
Small-molecule Bcl-2 antagonists as targeted therapy in oncology.
|
| |
Curr Oncol, 15,
256-261.
|
|
|
|
|
|
|
N.Y.Liu,
Z.F.Zhang,
and
W.C.Yang
(2008).
Isolation of embryo-specific mutants in Arabidopsis: plant transformation.
|
| |
Methods Mol Biol, 427,
91.
|
|
|
|
|
|
|
R.J.Youle,
and
A.Strasser
(2008).
The BCL-2 protein family: opposing activities that mediate cell death.
|
| |
Nat Rev Mol Cell Biol, 9,
47-59.
|
|
|
|
|
|
|
R.Tehranian,
M.E.Rose,
V.Vagni,
A.M.Pickrell,
R.P.Griffith,
H.Liu,
R.S.Clark,
C.E.Dixon,
P.M.Kochanek,
and
S.H.Graham
(2008).
Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury.
|
| |
J Neurotrauma, 25,
755-767.
|
|
|
|
|
|
|
S.K.Kolluri,
X.Zhu,
X.Zhou,
B.Lin,
Y.Chen,
K.Sun,
X.Tian,
J.Town,
X.Cao,
F.Lin,
D.Zhai,
S.Kitada,
F.Luciano,
E.O'Donnell,
Y.Cao,
F.He,
J.Lin,
J.C.Reed,
A.C.Satterthwait,
and
X.K.Zhang
(2008).
A short Nur77-derived peptide converts Bcl-2 from a protector to a killer.
|
| |
Cancer Cell, 14,
285-298.
|
|
|
|
|
|
|
S.Kneissl,
E.J.Loveridge,
C.Williams,
M.P.Crump,
and
R.K.Allemann
(2008).
Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
|
| |
Chembiochem, 9,
3046-3054.
|
|
|
|
|
|
|
S.Sinha,
and
B.Levine
(2008).
The autophagy effector Beclin 1: a novel BH3-only protein.
|
| |
Oncogene, 27,
S137-S148.
|
|
|
|
|
|
|
S.Sinha,
C.L.Colbert,
N.Becker,
Y.Wei,
and
B.Levine
(2008).
Molecular basis of the regulation of Beclin 1-dependent autophagy by the gamma-herpesvirus 68 Bcl-2 homolog M11.
|
| |
Autophagy, 4,
989-997.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
T.N.Chonghaile,
and
A.Letai
(2008).
Mimicking the BH3 domain to kill cancer cells.
|
| |
Oncogene, 27,
S149-S157.
|
|
|
|
|
|
|
V.N.Uversky,
C.J.Oldfield,
and
A.K.Dunker
(2008).
Intrinsically disordered proteins in human diseases: introducing the D2 concept.
|
| |
Annu Rev Biophys, 37,
215-246.
|
|
|
|
|
|
|
W.S.Horne,
and
S.H.Gellman
(2008).
Foldamers with heterogeneous backbones.
|
| |
Acc Chem Res, 41,
1399-1408.
|
|
|
|
|
|
|
Y.Feng,
X.Shen,
K.Chen,
H.Jiang,
and
D.Liu
(2008).
A new assay based on fluorescence resonance energy transfer to determine the binding affinity of Bcl-xL inhibitors.
|
| |
Biosci Biotechnol Biochem, 72,
1936-1939.
|
|
|
|
|
|
|
Y.W.Lu,
Y.D.Ren,
J.Bai,
and
W.N.Chen
(2008).
The spliced variant of hepatitis B virus protein, HBSP, interacts with Bcl-2/Bcl-xl in vitro and induces apoptosis in HepG2 cells.
|
| |
IUBMB Life, 60,
700-702.
|
|
|
|
|
|
|
A.E.Douglas,
K.D.Corbett,
J.M.Berger,
G.McFadden,
and
T.M.Handel
(2007).
Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2.
|
| |
Protein Sci, 16,
695-703.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
A.J.Dowling,
N.R.Waterfield,
M.C.Hares,
G.Le Goff,
C.H.Streuli,
and
R.H.ffrench-Constant
(2007).
The Mcf1 toxin induces apoptosis via the mitochondrial pathway and apoptosis is attenuated by mutation of the BH3-like domain.
|
| |
Cell Microbiol, 9,
2470-2484.
|
|
|
|
|
|
|
A.L.Pauleau,
N.Larochette,
F.Giordanetto,
S.R.Scholz,
D.Poncet,
N.Zamzami,
V.S.Goldmacher,
and
G.Kroemer
(2007).
Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA.
|
| |
Oncogene, 26,
7067-7080.
|
|
|
|
|
|
|
A.Mukhopadhyay,
and
H.Weiner
(2007).
Delivery of drugs and macromolecules to mitochondria.
|
| |
Adv Drug Deliv Rev, 59,
729-738.
|
|
|
|
|
|
|
B.Leber,
J.Lin,
and
D.W.Andrews
(2007).
Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes.
|
| |
Apoptosis, 12,
897-911.
|
|
|
|
|
|
|
C.Aisenbrey,
U.S.Sudheendra,
H.Ridley,
P.Bertani,
A.Marquette,
S.Nedelkina,
J.H.Lakey,
and
B.Bechinger
(2007).
Helix orientations in membrane-associated Bcl-X(L) determined by 15N-solid-state NMR spectroscopy.
|
| |
Eur Biophys J, 37,
71-80.
|
|
|
|
|
|
|
C.Xing,
L.Wang,
X.Tang,
and
Y.Y.Sham
(2007).
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.
|
| |
Bioorg Med Chem, 15,
2167-2176.
|
|
|
|
|
|
|
D.Westphal,
E.C.Ledgerwood,
M.H.Hibma,
S.B.Fleming,
E.M.Whelan,
and
A.A.Mercer
(2007).
A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.
|
| |
J Virol, 81,
7178-7188.
|
|
|
|
|
|
|
E.F.Lee,
P.E.Czabotar,
B.J.Smith,
K.Deshayes,
K.Zobel,
P.M.Colman,
and
W.D.Fairlie
(2007).
Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
|
| |
Cell Death Differ, 14,
1711-1713.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
E.Schmitt,
C.Paquet,
M.Beauchemin,
and
R.Bertrand
(2007).
DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis.
|
| |
J Zhejiang Univ Sci B, 8,
377-397.
|
|
|
|
|
|
|
F.W.Peyerl,
S.Dai,
G.A.Murphy,
F.Crawford,
J.White,
P.Marrack,
and
J.W.Kappler
(2007).
Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex.
|
| |
Cell Death Differ, 14,
447-452.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
G.Tang,
C.Y.Yang,
Z.Nikolovska-Coleska,
J.Guo,
S.Qiu,
R.Wang,
W.Gao,
G.Wang,
J.Stuckey,
K.Krajewski,
S.Jiang,
P.P.Roller,
and
S.Wang
(2007).
Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
|
| |
J Med Chem, 50,
1723-1726.
|
|
|
|
|
|
|
G.Tang,
K.Ding,
Z.Nikolovska-Coleska,
C.Y.Yang,
S.Qiu,
S.Shangary,
R.Wang,
J.Guo,
W.Gao,
J.Meagher,
J.Stuckey,
K.Krajewski,
S.Jiang,
P.P.Roller,
and
S.Wang
(2007).
Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins.
|
| |
J Med Chem, 50,
3163-3166.
|
|
|
|
|
|
|
H.Saito,
S.Kashida,
T.Inoue,
and
K.Shiba
(2007).
The role of peptide motifs in the evolution of a protein network.
|
| |
Nucleic Acids Res, 35,
6357-6366.
|
|
|
|
|
|
|
H.Saito,
T.Minamisawa,
and
K.Shiba
(2007).
Motif programming: a microgene-based method for creating synthetic proteins containing multiple functional motifs.
|
| |
Nucleic Acids Res, 35,
e38.
|
|
|
|
|
|
|
H.Xie,
S.Vucetic,
L.M.Iakoucheva,
C.J.Oldfield,
A.K.Dunker,
V.N.Uversky,
and
Z.Obradovic
(2007).
Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions.
|
| |
J Proteome Res, 6,
1882-1898.
|
|
|
|
|
|
|
J.A.Wells,
and
C.L.McClendon
(2007).
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
|
| |
Nature, 450,
1001-1009.
|
|
|
|
|
|
|
J.D.Sadowsky,
J.K.Murray,
Y.Tomita,
and
S.H.Gellman
(2007).
Exploration of backbone space in foldamers containing alpha- and beta-amino acid residues: developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL.
|
| |
Chembiochem, 8,
903-916.
|
|
|
|
|
|
|
J.Deng,
N.Carlson,
K.Takeyama,
P.Dal Cin,
M.Shipp,
and
A.Letai
(2007).
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
|
| |
Cancer Cell, 12,
171-185.
|
|
|
|
|
|
|
J.Doumanis,
L.Dorstyn,
and
S.Kumar
(2007).
Molecular determinants of the subcellular localization of the Drosophila Bcl-2 homologues DEBCL and BUFFY.
|
| |
Cell Death Differ, 14,
907-915.
|
|
|
|
|
|
|
J.L.Mott,
and
G.J.Gores
(2007).
Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death.
|
| |
Hepatology, 46,
906-911.
|
|
|
|
|
|
|
J.M.Adams,
and
S.Cory
(2007).
The Bcl-2 apoptotic switch in cancer development and therapy.
|
| |
Oncogene, 26,
1324-1337.
|
|
|
|
|
|
|
J.M.Davis,
L.K.Tsou,
and
A.D.Hamilton
(2007).
Synthetic non-peptide mimetics of alpha-helices.
|
| |
Chem Soc Rev, 36,
326-334.
|
|
|
|
|
|
|
J.Zhang,
and
G.T.Bowden
(2007).
Targeting Bcl-X(L) for prevention and therapy of skin cancer.
|
| |
Mol Carcinog, 46,
665-670.
|
|
|
|
|
|
|
L.Lalier,
P.F.Cartron,
P.Juin,
S.Nedelkina,
S.Manon,
B.Bechinger,
and
F.M.Vallette
(2007).
Bax activation and mitochondrial insertion during apoptosis.
|
| |
Apoptosis, 12,
887-896.
|
|
|
|
|
|
|
L.Zhang,
L.Ming,
and
J.Yu
(2007).
BH3 mimetics to improve cancer therapy; mechanisms and examples.
|
| |
Drug Resist Updat, 10,
207-217.
|
|
|
|
|
|
|
M.Aoyagi,
D.Zhai,
C.Jin,
A.E.Aleshin,
B.Stec,
J.C.Reed,
and
R.C.Liddington
(2007).
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein.
|
| |
Protein Sci, 16,
118-124.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
M.F.Rega,
M.Leone,
D.Jung,
N.J.Cotton,
J.L.Stebbins,
and
M.Pellecchia
(2007).
Structure-based discovery of a new class of Bcl-xL antagonists.
|
| |
Bioorg Chem, 35,
344-353.
|
|
|
|
|
|
|
M.G.Hinds,
C.Smits,
R.Fredericks-Short,
J.M.Risk,
M.Bailey,
D.C.Huang,
and
C.L.Day
(2007).
Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets.
|
| |
Cell Death Differ, 14,
128-136.
|
|
|
|
|
|
|
M.Kvansakul,
M.F.van Delft,
E.F.Lee,
J.M.Gulbis,
W.D.Fairlie,
D.C.Huang,
and
P.M.Colman
(2007).
A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak.
|
| |
Mol Cell, 25,
933-942.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
N.M.George,
J.J.Evans,
and
X.Luo
(2007).
A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax.
|
| |
Genes Dev, 21,
1937-1948.
|
|
|
|
|
|
|
N.Parikh,
C.Koshy,
V.Dhayabaran,
L.R.Perumalsamy,
R.Sowdhamini,
and
A.Sarin
(2007).
The N-terminus and alpha-5, alpha-6 helices of the pro-apoptotic protein Bax, modulate functional interactions with the anti-apoptotic protein Bcl-xL.
|
| |
BMC Cell Biol, 8,
16.
|
|
|
|
|
|
|
P.E.Czabotar,
E.F.Lee,
M.F.van Delft,
C.L.Day,
B.J.Smith,
D.C.Huang,
W.D.Fairlie,
M.G.Hinds,
and
P.M.Colman
(2007).
Structural insights into the degradation of Mcl-1 induced by BH3 domains.
|
| |
Proc Natl Acad Sci U S A, 104,
6217-6222.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
R.T.Uren,
G.Dewson,
L.Chen,
S.C.Coyne,
D.C.Huang,
J.M.Adams,
and
R.M.Kluck
(2007).
Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak.
|
| |
J Cell Biol, 177,
277-287.
|
|
|
|
|
|
|
S.Cooray,
M.W.Bahar,
N.G.Abrescia,
C.E.McVey,
N.W.Bartlett,
R.A.Chen,
D.I.Stuart,
J.M.Grimes,
and
G.L.Smith
(2007).
Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein.
|
| |
J Gen Virol, 88,
1656-1666.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
S.M.Biros,
L.Moisan,
E.Mann,
A.Carella,
D.Zhai,
J.C.Reed,
and
J.Rebek
(2007).
Heterocyclic alpha-helix mimetics for targeting protein-protein interactions.
|
| |
Bioorg Med Chem Lett, 17,
4641-4645.
|
|
|
|
|
|
|
S.W.Tait,
E.de Vries,
C.Maas,
A.M.Keller,
C.S.D'Santos,
and
J.Borst
(2007).
Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment.
|
| |
J Cell Biol, 179,
1453-1466.
|
|
|
|
|
|
|
T.J.Malia,
and
G.Wagner
(2007).
NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL.
|
| |
Biochemistry, 46,
514-525.
|
|
|
|
|
|
|
X.Fu,
J.R.Apgar,
and
A.E.Keating
(2007).
Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.
|
| |
J Mol Biol, 371,
1099-1117.
|
|
|
|
|
|
|
X.Li,
L.Hong,
Y.Zhao,
H.Jin,
R.Fan,
R.Du,
L.Xia,
G.Luo,
and
D.Fan
(2007).
A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
|
| |
Biochem Cell Biol, 85,
741-750.
|
|
|
|
|
|
|
Y.Horikawa,
M.Otaka,
K.Komatsu,
M.Jin,
M.Odashima,
I.Wada,
T.Matsuhashi,
R.Ohba,
J.Oyake,
N.Hatakeyama,
R.N.Dubois,
and
S.Watanabe
(2007).
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.
|
| |
Dig Dis Sci, 52,
2757-2765.
|
|
|
|
|
|
|
Y.W.Lu,
T.L.Tan,
J.Zhang,
and
W.N.Chen
(2007).
Cellular apoptosis induced by replication of hepatitis B virus: possible link between viral genotype and clinical outcome.
|
| |
Virol J, 4,
117.
|
|
|
|
|
|
|
A.Postigo,
J.R.Cross,
J.Downward,
and
M.Way
(2006).
Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis.
|
| |
Cell Death Differ, 13,
1651-1662.
|
|
|
|
|
|
|
B.Becattini,
C.Culmsee,
M.Leone,
D.Zhai,
X.Zhang,
K.J.Crowell,
M.F.Rega,
S.Landshamer,
J.C.Reed,
N.Plesnila,
and
M.Pellecchia
(2006).
Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid.
|
| |
Proc Natl Acad Sci U S A, 103,
12602-12606.
|
|
|
|
|
|
|
C.Tan,
P.J.Dlugosz,
J.Peng,
Z.Zhang,
S.M.Lapolla,
S.M.Plafker,
D.W.Andrews,
and
J.Lin
(2006).
Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2.
|
| |
J Biol Chem, 281,
14764-14775.
|
|
|
|
|
|
|
D.C.Fry
(2006).
Protein-protein interactions as targets for small molecule drug discovery.
|
| |
Biopolymers, 84,
535-552.
|
|
|
|
|
|
|
D.P.Frazier,
A.Wilson,
R.M.Graham,
J.W.Thompson,
N.H.Bishopric,
and
K.A.Webster
(2006).
Acidosis regulates the stability, hydrophobicity, and activity of the BH3-only protein Bnip3.
|
| |
Antioxid Redox Signal, 8,
1625-1634.
|
|
|
|
|
|
|
D.Wang,
K.Chen,
G.Dimartino,
and
P.S.Arora
(2006).
Nucleation and stability of hydrogen-bond surrogate-based alpha-helices.
|
| |
Org Biomol Chem, 4,
4074-4081.
|
|
|
|
|
|
|
D.Wang,
K.Chen,
J.L.Kulp Iii,
and
P.S.Arora
(2006).
Evaluation of biologically relevant short alpha-helices stabilized by a main-chain hydrogen-bond surrogate.
|
| |
J Am Chem Soc, 128,
9248-9256.
|
|
|
|
|
|
|
D.Zhai,
C.Jin,
A.C.Satterthwait,
and
J.C.Reed
(2006).
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins.
|
| |
Cell Death Differ, 13,
1419-1421.
|
|
|
|
|
|
|
G.R.Thuduppathy,
and
R.B.Hill
(2006).
Acid destabilization of the solution conformation of Bcl-xL does not drive its pH-dependent insertion into membranes.
|
| |
Protein Sci, 15,
248-257.
|
|
|
|
|
|
|
H.Ji,
A.Shekhtman,
R.Ghose,
J.M.McDonnell,
and
D.Cowburn
(2006).
NMR determination that an extended BH3 motif of pro-apoptotic BID is specifically bound to BCL-XL.
|
| |
Magn Reson Chem, 44,
S101-S107.
|
|
|
|
|
|
|
H.L.Galonek,
and
J.M.Hardwick
(2006).
Upgrading the BCL-2 network.
|
| |
Nat Cell Biol, 8,
1317-1319.
|
|
|
|
|
|
|
I.Sturm,
C.Stephan,
B.Gillissen,
R.Siebert,
M.Janz,
S.Radetzki,
K.Jung,
S.Loening,
B.Dörken,
and
P.T.Daniel
(2006).
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.
|
| |
Cell Death Differ, 13,
619-627.
|
|
|
|
|
|
|
J.I.Fletcher,
and
D.C.Huang
(2006).
BH3-only proteins: orchestrating cell death.
|
| |
Cell Death Differ, 13,
1268-1271.
|
|
|
|
|
|
|
J.Pardo,
C.Urban,
E.M.Galvez,
P.G.Ekert,
U.Müller,
J.Kwon-Chung,
M.Lobigs,
A.Müllbacher,
R.Wallich,
C.Borner,
and
M.M.Simon
(2006).
The mitochondrial protein Bak is pivotal for gliotoxin-induced apoptosis and a critical host factor of Aspergillus fumigatus virulence in mice.
|
| |
J Cell Biol, 174,
509-519.
|
|
|
|
|
|
|
J.Peng,
C.Tan,
G.J.Roberts,
O.Nikolaeva,
Z.Zhang,
S.M.Lapolla,
S.Primorac,
D.W.Andrews,
and
J.Lin
(2006).
tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation.
|
| |
J Biol Chem, 281,
35802-35811.
|
|
|
|
|
|
|
J.Su,
G.Wang,
J.W.Barrett,
T.S.Irvine,
X.Gao,
and
G.McFadden
(2006).
Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria.
|
| |
J Virol, 80,
1140-1151.
|
|
|
|
|
|
|
L.D.Walensky
(2006).
BCL-2 in the crosshairs: tipping the balance of life and death.
|
| |
Cell Death Differ, 13,
1339-1350.
|
|
|
|
|
|
|
L.D.Walensky,
K.Pitter,
J.Morash,
K.J.Oh,
S.Barbuto,
J.Fisher,
E.Smith,
G.L.Verdine,
and
S.J.Korsmeyer
(2006).
A stapled BID BH3 helix directly binds and activates BAX.
|
| |
Mol Cell, 24,
199-210.
|
|
|
|
|
|
|
L.R.Kidd,
A.Coulibaly,
T.M.Templeton,
W.Chen,
L.O.Long,
T.Mason,
C.Bonilla,
F.Akereyeni,
V.Freeman,
W.Isaacs,
C.Ahaghotu,
and
R.A.Kittles
(2006).
Germline BCL-2 sequence variants and inherited predisposition to prostate cancer.
|
| |
Prostate Cancer Prostatic Dis, 9,
284-292.
|
|
|
|
|
|
|
L.Yu,
P.J.Hajduk,
J.Mack,
and
E.T.Olejniczak
(2006).
Structural studies of Bcl-xL/ligand complexes using 19F NMR.
|
| |
J Biomol NMR, 34,
221-227.
|
|
|
|
|
|
|
M.Certo,
V.Del Gaizo Moore,
M.Nishino,
G.Wei,
S.Korsmeyer,
S.A.Armstrong,
and
A.Letai
(2006).
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
|
| |
Cancer Cell, 9,
351-365.
|
|
|
|
|
|
|
M.F.van Delft,
A.H.Wei,
K.D.Mason,
C.J.Vandenberg,
L.Chen,
P.E.Czabotar,
S.N.Willis,
C.L.Scott,
C.L.Day,
S.Cory,
J.M.Adams,
A.W.Roberts,
and
D.C.Huang
(2006).
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
|
| |
Cancer Cell, 10,
389-399.
|
|
|
|
|
|
|
M.F.van Delft,
and
D.C.Huang
(2006).
How the Bcl-2 family of proteins interact to regulate apoptosis.
|
| |
Cell Res, 16,
203-213.
|
|
|
|
|
|
|
M.Reibarkh,
T.J.Malia,
B.T.Hopkins,
and
G.Wagner
(2006).
Identification of individual protein-ligand NOEs in the limit of intermediate exchange.
|
| |
J Biomol NMR, 36,
1.
|
|
|
|
|
|
|
O.Kutuk,
and
H.Basaga
(2006).
Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis.
|
| |
Apoptosis, 11,
1661-1675.
|
|
|
|
|
|
|
P.H.Schlesinger,
and
M.Saito
(2006).
The Bax pore in liposomes, Biophysics.
|
| |
Cell Death Differ, 13,
1403-1408.
|
|
|
|
|
|
|
P.S.Schwartz,
and
D.M.Hockenbery
(2006).
Bcl-2-related survival proteins.
|
| |
Cell Death Differ, 13,
1250-1255.
|
|
|
|
|
|
|
S.F.Fischer,
H.Ludwig,
J.Holzapfel,
M.Kvansakul,
L.Chen,
D.C.Huang,
G.Sutter,
M.Knese,
and
G.Häcker
(2006).
Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis.
|
| |
Cell Death Differ, 13,
109-118.
|
|
|
|
|
|
|
S.Fletcher,
and
A.D.Hamilton
(2006).
Targeting protein-protein interactions by rational design: mimicry of protein surfaces.
|
| |
J R Soc Interface, 3,
215-233.
|
|
|
|
|
|
|
S.P.Brown,
and
P.J.Hajduk
(2006).
Effects of conformational dynamics on predicted protein druggability.
|
| |
ChemMedChem, 1,
70-72.
|
|
|
|
|
|
|
T.Shibue,
and
T.Taniguchi
(2006).
BH3-only proteins: integrated control point of apoptosis.
|
| |
Int J Cancer, 119,
2036-2043.
|
|
|
|
|
|
|
W.D.Fairlie,
M.A.Perugini,
M.Kvansakul,
L.Chen,
D.C.Huang,
and
P.M.Colman
(2006).
CED-4 forms a 2 : 2 heterotetrameric complex with CED-9 until specifically displaced by EGL-1 or CED-13.
|
| |
Cell Death Differ, 13,
426-434.
|
|
|
|
|
|
|
Y.K.Verma,
G.U.Gangenahalli,
V.K.Singh,
P.Gupta,
R.Chandra,
R.K.Sharma,
and
H.G.Raj
(2006).
Cell death regulation by B-cell lymphoma protein.
|
| |
Apoptosis, 11,
459-471.
|
|
|
|
|
|
|
A.Letai
(2005).
Pharmacological manipulation of Bcl-2 family members to control cell death.
|
| |
J Clin Invest, 115,
2648-2655.
|
|
|
|
|
|
|
A.Loregian,
and
G.Palù
(2005).
Disruption of protein-protein interactions: towards new targets for chemotherapy.
|
| |
J Cell Physiol, 204,
750-762.
|
|
|
|
|
|
|
A.M.Petros,
S.W.Fesik,
and
E.T.Olejniczak
(2005).
1H, 13C and 15N resonance assignments of a Bcl-xL/Bad peptide complex.
|
| |
J Biomol NMR, 32,
260.
|
|
|
|
|
|
|
D.C.Fry,
and
L.T.Vassilev
(2005).
Targeting protein-protein interactions for cancer therapy.
|
| |
J Mol Med, 83,
955-963.
|
|
|
|
|
|
|
D.Wang,
W.Liao,
and
P.S.Arora
(2005).
Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL.
|
| |
Angew Chem Int Ed Engl, 44,
6525-6529.
|
|
|
|
|
|
|
G.B.Smith,
and
E.S.Mocarski
(2005).
Contribution of GADD45 family members to cell death suppression by cellular Bcl-xL and cytomegalovirus vMIA.
|
| |
J Virol, 79,
14923-14932.
|
|
|
|
|
|
|
G.Packham,
and
F.K.Stevenson
(2005).
Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.
|
| |
Immunology, 114,
441-449.
|
|
|
|
|
|
|
H.S.Vatansever,
S.Lacin,
and
M.K.Ozbilgin
(2005).
Changed Bcl:Bax ratio in endometrium of patients with unexplained infertility.
|
| |
Acta Histochem, 107,
345-355.
|
|
|
|
|
|
|
H.Yin,
and
A.D.Hamilton
(2005).
Strategies for targeting protein-protein interactions with synthetic agents.
|
| |
Angew Chem Int Ed Engl, 44,
4130-4163.
|
|
|
|
|
|
|
H.Yin,
G.I.Lee,
H.S.Park,
G.A.Payne,
J.M.Rodriguez,
S.M.Sebti,
and
A.D.Hamilton
(2005).
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.
|
| |
Angew Chem Int Ed Engl, 44,
2704-2707.
|
|
|
|
|
|
|
J.L.Mott,
D.Zhang,
and
H.P.Zassenhaus
(2005).
Mitochondrial DNA mutations, apoptosis, and the misfolded protein response.
|
| |
Rejuvenation Res, 8,
216-226.
|
|
|
|
|
|
|
J.Loh,
Q.Huang,
A.M.Petros,
D.Nettesheim,
L.F.van Dyk,
L.Labrada,
S.H.Speck,
B.Levine,
E.T.Olejniczak,
and
H.W.Virgin
(2005).
A surface groove essential for viral Bcl-2 function during chronic infection in vivo.
|
| |
PLoS Pathog, 1,
e10.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
K.O.Tan,
N.Y.Fu,
S.K.Sukumaran,
S.L.Chan,
J.H.Kang,
K.L.Poon,
B.S.Chen,
and
V.C.Yu
(2005).
MAP-1 is a mitochondrial effector of Bax.
|
| |
Proc Natl Acad Sci U S A, 102,
14623-14628.
|
|
|
|
|
|
|
L.Chen,
S.N.Willis,
A.Wei,
B.J.Smith,
J.I.Fletcher,
M.G.Hinds,
P.M.Colman,
C.L.Day,
J.M.Adams,
and
D.C.Huang
(2005).
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
|
| |
Mol Cell, 17,
393-403.
|
|
|
|
|
|
|
M.Bras,
B.Queenan,
and
S.A.Susin
(2005).
Programmed cell death via mitochondria: different modes of dying.
|
| |
Biochemistry (Mosc), 70,
231-239.
|
|
|
|
|
|
|
M.Klee,
and
F.X.Pimentel-Muiños
(2005).
Bcl-X(L) specifically activates Bak to induce swelling and restructuring of the endoplasmic reticulum.
|
| |
J Cell Biol, 168,
723-734.
|
|
|
|
|
|
|
N.Yan,
and
Y.Shi
(2005).
Mechanisms of apoptosis through structural biology.
|
| |
Annu Rev Cell Dev Biol, 21,
35-56.
|
|
|
|
|
|
|
S.N.Willis,
L.Chen,
G.Dewson,
A.Wei,
E.Naik,
J.I.Fletcher,
J.M.Adams,
and
D.C.Huang
(2005).
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.
|
| |
Genes Dev, 19,
1294-1305.
|
|
|
|
|
|
|
S.W.Fesik
(2005).
Promoting apoptosis as a strategy for cancer drug discovery.
|
| |
Nat Rev Cancer, 5,
876-885.
|
|
|
|
|
|
|
T.Oltersdorf,
S.W.Elmore,
A.R.Shoemaker,
R.C.Armstrong,
D.J.Augeri,
B.A.Belli,
M.Bruncko,
T.L.Deckwerth,
J.Dinges,
P.J.Hajduk,
M.K.Joseph,
S.Kitada,
S.J.Korsmeyer,
A.R.Kunzer,
A.Letai,
C.Li,
M.J.Mitten,
D.G.Nettesheim,
S.Ng,
P.M.Nimmer,
J.M.O'Connor,
A.Oleksijew,
A.M.Petros,
J.C.Reed,
W.Shen,
S.K.Tahir,
C.B.Thompson,
K.J.Tomaselli,
B.Wang,
M.D.Wendt,
H.Zhang,
S.W.Fesik,
and
S.H.Rosenberg
(2005).
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
|
| |
Nature, 435,
677-681.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
A.Egle,
A.W.Harris,
P.Bouillet,
and
S.Cory
(2004).
Bim is a suppressor of Myc-induced mouse B cell leukemia.
|
| |
Proc Natl Acad Sci U S A, 101,
6164-6169.
|
|
|
|
|
|
|
A.J.Watson
(2004).
Apoptosis and colorectal cancer.
|
| |
Gut, 53,
1701-1709.
|
|
|
|
|
|
|
A.K.Galande,
K.S.Bramlett,
T.P.Burris,
J.L.Wittliff,
and
A.F.Spatola
(2004).
Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions.
|
| |
J Pept Res, 63,
297-302.
|
|
|
|
|
|
|
B.Becattini,
S.Kitada,
M.Leone,
E.Monosov,
S.Chandler,
D.Zhai,
T.J.Kipps,
J.C.Reed,
and
M.Pellecchia
(2004).
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).
|
| |
Chem Biol, 11,
389-395.
|
|
|
|
|
|
|
B.Becattini,
S.Sareth,
D.Zhai,
K.J.Crowell,
M.Leone,
J.C.Reed,
and
M.Pellecchia
(2004).
Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules.
|
| |
Chem Biol, 11,
1107-1117.
|
|
|
|
|
|
|
B.Lin,
S.K.Kolluri,
F.Lin,
W.Liu,
Y.H.Han,
X.Cao,
M.I.Dawson,
J.C.Reed,
and
X.K.Zhang
(2004).
Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.
|
| |
Cell, 116,
527-540.
|
|
|
|
|
|
|
C.M.Franzin,
J.Choi,
D.Zhai,
J.C.Reed,
and
F.M.Marassi
(2004).
Structural studies of apoptosis and ion transport regulatory proteins in membranes.
|
| |
Magn Reson Chem, 42,
172-179.
|
|
|
|
|
|
|
D.G.Breckenridge,
and
D.Xue
(2004).
Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases.
|
| |
Curr Opin Cell Biol, 16,
647-652.
|
|
|
|
|
|
|
D.Hockenbery
(2004).
Breaking down tumor defenses.
|
| |
Chem Biol, 11,
417-418.
|
|
|
|
|
|
|
E.A.Jonas,
J.A.Hickman,
M.Chachar,
B.M.Polster,
T.A.Brandt,
Y.Fannjiang,
I.Ivanovska,
G.Basañez,
K.W.Kinnally,
J.Zimmerberg,
J.M.Hardwick,
and
L.K.Kaczmarek
(2004).
Proapoptotic N-truncated BCL-xL protein activates endogenous mitochondrial channels in living synaptic terminals.
|
| |
Proc Natl Acad Sci U S A, 101,
13590-13595.
|
|
|
|
|
|
|
F.J.Stevens
(2004).
Hypothetical structure of human serum amyloid A protein.
|
| |
Amyloid, 11,
71-80.
|
|
|
|
|
|
|
G.Wang,
J.W.Barrett,
S.H.Nazarian,
H.Everett,
X.Gao,
C.Bleackley,
K.Colwill,
M.F.Moran,
and
G.McFadden
(2004).
Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak.
|
| |
J Virol, 78,
7097-7111.
|
|
|
|
|
|
|
J.I.Leu,
P.Dumont,
M.Hafey,
M.E.Murphy,
and
D.L.George
(2004).
Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex.
|
| |
Nat Cell Biol, 6,
443-450.
|
|
|
|
|
|
|
J.O'Neill,
M.Manion,
P.Schwartz,
and
D.M.Hockenbery
(2004).
Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy.
|
| |
Biochim Biophys Acta, 1705,
43-51.
|
|
|
|
|
|
|
L.D.Walensky,
A.L.Kung,
I.Escher,
T.J.Malia,
S.Barbuto,
R.D.Wright,
G.Wagner,
G.L.Verdine,
and
S.J.Korsmeyer
(2004).
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.
|
| |
Science, 305,
1466-1470.
|
|
|
|
|
|
|
M.R.Arkin,
and
J.A.Wells
(2004).
Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.
|
| |
Nat Rev Drug Discov, 3,
301-317.
|
|
|
|
|
|
|
N.Liu,
X.M.Xu,
J.Chen,
L.Wang,
S.Yang,
C.B.Underhill,
and
L.Zhang
(2004).
Hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2.
|
| |
Int J Cancer, 109,
49-57.
|
|
|
|
|
|
|
N.Yan,
L.Gu,
D.Kokel,
J.Chai,
W.Li,
A.Han,
L.Chen,
D.Xue,
and
Y.Shi
(2004).
Structural, biochemical, and functional analyses of CED-9 recognition by the proapoptotic proteins EGL-1 and CED-4.
|
| |
Mol Cell, 15,
999.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
S.L.Chan,
and
V.C.Yu
(2004).
Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.
|
| |
Clin Exp Pharmacol Physiol, 31,
119-128.
|
|
|
|
|
|
|
S.Y.Jeong,
B.Gaume,
Y.J.Lee,
Y.T.Hsu,
S.W.Ryu,
S.H.Yoon,
and
R.J.Youle
(2004).
Bcl-x(L) sequesters its C-terminal membrane anchor in soluble, cytosolic homodimers.
|
| |
EMBO J, 23,
2146-2155.
|
|
|
|
|
|
|
Y.Zhu,
B.J.Swanson,
M.Wang,
D.A.Hildeman,
B.C.Schaefer,
X.Liu,
H.Suzuki,
K.Mihara,
J.Kappler,
and
P.Marrack
(2004).
Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells.
|
| |
Proc Natl Acad Sci U S A, 101,
7681-7686.
|
|
|
|
|
|
|
Z.Zhang,
S.M.Lapolla,
M.G.Annis,
M.Truscott,
G.J.Roberts,
Y.Miao,
Y.Shao,
C.Tan,
J.Peng,
A.E.Johnson,
X.C.Zhang,
D.W.Andrews,
and
J.Lin
(2004).
Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax.
|
| |
J Biol Chem, 279,
43920-43928.
|
|
|
|
|
|
|
A.Burlacu
(2003).
Regulation of apoptosis by Bcl-2 family proteins.
|
| |
J Cell Mol Med, 7,
249-257.
|
|
|
|
|
|
|
A.Letai
(2003).
BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.
|
| |
Expert Opin Biol Ther, 3,
293-304.
|
|
|
|
|
|
|
J.Wilson-Annan,
L.A.O'Reilly,
S.A.Crawford,
G.Hausmann,
J.G.Beaumont,
L.P.Parma,
L.Chen,
M.Lackmann,
T.Lithgow,
M.G.Hinds,
C.L.Day,
J.M.Adams,
and
D.C.Huang
(2003).
Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity.
|
| |
J Cell Biol, 162,
877-887.
|
|
|
|
|
|
|
L.Coultas,
and
A.Strasser
(2003).
The role of the Bcl-2 protein family in cancer.
|
| |
Semin Cancer Biol, 13,
115-123.
|
|
|
|
|
|
|
M.G.Hinds,
M.Lackmann,
G.L.Skea,
P.J.Harrison,
D.C.Huang,
and
C.L.Day
(2003).
The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity.
|
| |
EMBO J, 22,
1497-1507.
|
|
|
PDB code:
|
|
|
|
|
|
| |
Links
